乳腺浸润性导管癌中Ezrin和CD44 v6的表达及临床意义

摘要

Objective:To investigate the expression of Ezrin and CD44v6 and their association with clinical pathological features in breast invasive ductal carcinoma. Methods:Immunohistochemistry was used to detect the expression of Ezrin and CD44v6 in 95 cases of breast invasive ductal carcinoma and 30 cases of normal breast tissue. Results:The positive rates of Ezrin and CD44v6 were 62. 1% and 58. 9% in breast invasive ductal carcinoma respectively,which were much higher than those 23. 3% and 16. 7% in normal breast tissue(P﹤0. 05). The expression of Ezrin and CD44v6 was significantly correlated to lymph node metastasis and TNM stage( P ﹤ 0 . 0 5 ),but it was not related to the age ,tumor size and histolgical degree( P ﹥0. 05). The expression of Ezrin was directly postive correlated to that of CD44v6 in breast invasive ductal carcinoma(P﹥0. 05). Conclusion:Abnormal expression of Ezrin and CD44v6 maybe cooperative effects in development and metastasis of breast inva-sive ductal carcinoma. Combined analysis of these molecules is useful to estimatin of malignancy and metastatic potential of breast cancer.%目的：探讨Ezrin和CD44v6在乳腺浸润性导管癌中的表达情况，探讨其与临床病理特征的关系。方法：应用免疫组化Envision法检测95例乳腺浸润性导管癌和30例正常乳腺组织中Ezrin和CD44v6的表达情况。结果：Ezrin和CD44v6在乳腺癌中的阳性率分别为62.1％和58.9％，明显高于正常乳腺组织中的23.3％和16.7％（P﹤0.05）。Ezrin和CD44v6在乳腺癌中的表达与淋巴结转移、临床分期密切相关（ P﹥0.05），与患者的年龄、肿瘤大小、组织分级无关（P﹥0.05）。在乳腺癌中Ezrin和CD44v6的表达呈正相关（P﹤0.05）。结论：Ezrin和CD44v6可能在乳腺浸润性导管癌的发展和转移中起协同作用，联合检测其表达情况有助于判断乳腺癌的恶性程度和转移潜能。